Pharmaceuticals, Biotechnology & Life Sciences

Incyte’s new once‑daily Jakafi XR gets FDA approval, offering same efficacy as the twice‑daily drug while easing dosing for myelofibrosis, polycythemia vera, and GVHD patients.

Thermo Fisher’s Q1 2026 results show modest revenue gains, steady profitability, and strategic investments in toxicology and genomic cancer testing—offering investors a disciplined, growth‑oriented outlook for the biotech diagnostics market.

Pfizer’s FDA approval of Veppanu expands its breast‑cancer portfolio, boosting oncology prospects and reinforcing its market position amid patent‑cliff pressures.

Explore how Novo Nordisk’s rebranding, new AUD research, and strategic distribution moves defend against generics, expand markets, and shape investor outlook.

Grifols SA: steady share growth, plasma‑derived therapies and robust EMA/FDA approvals show the Spanish biopharma firm’s blend of proven efficacy and strategic market positioning.

Illumina’s FY‑2026 Q1 shows modest revenue growth, stronger margins and a healthy cash flow, driven by NovaSeq X and cloud‑based genomics services, boosting investor confidence and long‑term growth potential.

Insider trades by UTH CEO Martina Rothblatt show no strategic shift, but the company faces patent cliffs for Macitentan. Learn how UTH plans pricing, pipeline, and M&A to protect growth and compete in pulmonary hypertension.

Merck KGaA names Kai Beckmann CEO to steer continuity amid volatile markets, balancing pharma, lab supplies and semiconductor growth while tackling AI‑driven R&D challenges.

FDA’s proposed removal of semaglutide and liraglutide from the 503B bulk‑list could boost Novo Nordisk’s pricing power, but raises competition and payer‑policy risks for investors to watch.

Teva’s Q1 2026 earnings show a 12% cash rise, strategic $700 m Emalex buy‑out, and a $500 m Blackstone‑backed duvakitug push, boosting R&D and niche revenue.